KEYNOTE-859: First-line treatment (pembrolizumab plus chemotherapy) of locally advanced unresectable or metastatic HER2- negative gastric or gastroesophageal junction adenocarcinoma
Supporting documentation
Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.